Opening an Opioid Treatment Program: The Four Approvals in Order

An opioid treatment program (OTP) cannot dispense methadone until four separate authorities have approved it: the state, SAMHSA, a SAMHSA-approved accrediting body and the Drug Enforcement Administration. SAMHSA's own requirement list is short: OTPs "must be both certified and accredited," licensed by the state where they operate, and registered with DEA. The hard part is that the approvals depend on each other. SAMHSA calls provisional certification "a triplicate process" in its OTP FAQs, because its approval "is contingent upon state and DEA approvals," and DEA's pre-registration visit checks for the state license and SAMHSA certification.

The 2024 National Substance Use and Mental Health Services Survey counted 2,224 federally certified OTPs among 15,953 substance use treatment facilities, 13.9 percent of them (SAMHSA, 2024 N-SUMHSS Annual Report). Every one of them went through the same four gates. Here is the order that keeps a new program from stalling between them.

What are the four approvals?

1. The state. A state license or certification for the program, plus the approval of the State Opioid Treatment Authority (SOTA), the agency the governor designates to govern OTP treatment in the state (42 CFR 8.2). Some states add a certificate of need, a need review or a moratorium before any of this.
2. SAMHSA certification. Applied for on Form SMA-162 through the OTP Extranet. A new program receives provisional certification for up to one year once it has applied for accreditation (42 CFR 8.11(d)).
3. OTP accreditation. A separate accreditation as an OTP from a SAMHSA-approved body. SAMHSA's FAQ is direct that an existing behavioral health accreditation cannot be reused.
4. DEA registration. Form 363 for a new narcotic treatment program, with a $296 fee and a one-year registration (21 CFR 1301.13(e)(1)(viii)). The program "must be registered by the DEA before administering or dispensing" (42 CFR 8.11(e)(6)).

Why does the state come first?

Federal rules leave the states in charge of whether an OTP may open at all. Part 8 says nothing in it "is intended to limit the authority of State and, as appropriate, local governmental entities to regulate the use of MOUD" (42 CFR 8.11(e)(1)), and SAMHSA consults the state authority about the applicant's qualifications before it certifies (8.11(c)(1)). In practice the state is the slowest and least predictable of the four, so it should start first.

A few states put a gate in front of the license:

• Tennessee requires a certificate of need before anyone establishes a nonresidential substitution-based treatment center for opiate addiction. A 2026 bill to remove that requirement, SB 2281, was sent to a Senate general subcommittee on March 31, 2026, and the General Assembly record shows no further action.
• West Virginia has had a moratorium on licensing new OTPs that lacked a certificate of need since 2016, which "shall continue until the Legislature determines that there is a necessity" for more (W. Va. Code 16B-13-12). Its certificate of need law also bars issuing one to an OTP, apart from a narrow clinical trial exception (16-2D-9(4)).
• Mississippi will not certify an OTP "in an area where needs are met by existing services," and the rule reaches later satellite and branch locations too (DMH Operational Standards, Rule 2.2(L)).
• New York approves a new program only if it finds "a public need for the services at the time and place" proposed (14 NYCRR 810.7(a)(1)), and Washington weighs the population in need, nearby OTPs and transportation before licensing (RCW 71.24.590).
• Louisiana went the other way: Act 232 of 2026 repealed its facility need review for OTPs, effective May 15, 2026.
• Georgia moved narcotic treatment program licensing to DBHDD on January 1, 2026. DBHDD takes NTP applications only during an open enrollment window, December 1 to December 31, 2026, and attendance at its October 7 forum was mandatory for applicants in that window.

Our post on certificate of need and need review for new OTPs walks through each of these. Your state page shows the authority, the license and any gate we have verified.

How do the federal applications overlap?

Once the state process is under way, the federal pieces run side by side rather than one after another. SAMHSA's FAQ tells applicants that while the SMA-162 is under review, "OTPs should complete applications for the respective DEA and State Inspections," and a SAMHSA compliance officer then collects approvals from both. Pennsylvania writes the same idea into its rule: application "shall be made simultaneously" to the state department, DEA and SAMHSA (28 Pa. Code 715.3(a)).

A sequence that works for most new programs:

1. Confirm the state gate (certificate of need, need review, moratorium or open enrollment) and the state license path.
2. Apply to an OTP accrediting body. Provisional certification requires that you have already applied, and the SMA-162 asks for the body's name, the date you applied and the expected survey schedule (8.11(d)).
3. Submit the SMA-162 for provisional certification, with the facility diagram, the medical director's DEA registration, state license and CV, and the other attachments SAMHSA lists. See SAMHSA's Form SMA-162, section by section.
4. File DEA Form 363 online. DEA's local field office schedules an on-site pre-registration investigation, tests security and verifies state licensure and SAMHSA certification, according to DEA's Narcotic Treatment Program Manual.
5. Receive provisional certification, then the DEA registration, then open. Within the provisional year, complete the accreditation survey and apply to SAMHSA for full certification.

Is SAMHSA's 45 days a deadline?

SAMHSA's FAQ says it "requests 45 days from the receipt of the provisional application to render a decision." That is SAMHSA's own clock, and it starts from a complete application. The same FAQ warns that incomplete applications take longer, and SAMHSA "will not grant provisional certification without state and DEA approvals." No one can promise a program an opening date, because the state and DEA set their own pace. What a program controls is sending a complete packet to every agency at the right moment.

Who signs each application?

• SMA-162: the program sponsor. The rule says the application "shall be signed by the program sponsor who shall certify that the information submitted in the application is truthful and accurate" (8.11(b)(7)), and SAMHSA's program-changes page says "Only an OTP program sponsor may sign and submit a Form SMA-162."
• DEA Form 363: an officer of a corporation, a partner of a partnership, or the individual applicant (21 CFR 1301.13(j)). DEA allows a power of attorney for other signers; we do not accept one.
• State license: the licensee's owner or officer, on the state's form. West Virginia's OTP application requires the applicant's notarized signature (W. Va. Code 16B-13-3).

Is the program finished once it opens?

No. Within the provisional year the program must be surveyed and accredited and move to full certification, which lasts up to three years (8.11(a)(3)). DEA registration renews every year on Form 363a. Changes in program sponsor or medical director go to SAMHSA within three weeks (8.11(e)(5)). And if the program wants Medicare patients' services paid, it enrolls on the CMS-855A or 855B once it holds full certification, because a provisional certification does not meet the enrollment standard (42 CFR 424.67(b)(4)). See Medicare enrollment for opioid treatment programs.

Where do new programs lose months?

• Starting federal work before the state gate is clear. In a certificate of need state, the rest of the work waits on that decision.
• Applying for certification before applying for accreditation. Provisional certification is only available to a program that has already applied to an accrediting body.
• A facility diagram that does not show the dispensing area clearly. DEA requires patients to wait in an area physically separated from narcotic storage and dispensing (21 CFR 1301.74(j)), and SAMHSA wants the dispensing and counseling space described.
• A medical director who is not yet on board. The SMA-162 needs the medical director's DEA registration, state license and CV.
• Extranet accounts set up late. SAMHSA expects the sponsor to hold an individual OTP Extranet account; the medical director needs one for exception requests.

How can we help, and what does it cost?

Our Opioid Treatment Program Approval Package is $6,995, plus the state license package ($1,995 for an outpatient program). We prepare the SMA-162 packet, the DEA Form 363 information, the OTP accreditation application and the state license file, and we sequence them so no agency waits on a missing piece. Your program sponsor signs and submits the SMA-162 from the sponsor's own Extranet account, an officer signs the DEA form, and you pay every state, DEA and accreditation fee directly. Every fee we charge is flat. A $149 Facility Readiness Review is the place to start if you are not sure which state gates apply. See the OTP approval hub and pricing.